These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

266 related articles for article (PubMed ID: 26813076)

  • 41. Combined BRAF and MEK inhibition for the treatment of BRAF-mutated metastatic melanoma.
    Queirolo P; Picasso V; Spagnolo F
    Cancer Treat Rev; 2015 Jun; 41(6):519-26. PubMed ID: 25944484
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Great advances in the systemic treatment in malignant melanoma patients].
    Ullenhag G; Hansson J; Ny L
    Lakartidningen; 2017 May; 114():. PubMed ID: 28485771
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The clinical significance of BRAF and NRAS mutations in a clinic-based metastatic melanoma cohort.
    Ekedahl H; Cirenajwis H; Harbst K; Carneiro A; Nielsen K; Olsson H; Lundgren L; Ingvar C; Jönsson G
    Br J Dermatol; 2013 Nov; 169(5):1049-55. PubMed ID: 23855428
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Prognostic and predictive values of oncogenic BRAF, NRAS, c-KIT and MITF in cutaneous and mucous melanoma.
    Pracht M; Mogha A; Lespagnol A; Fautrel A; Mouchet N; Le Gall F; Paumier V; Lefeuvre-Plesse C; Rioux-Leclerc N; Mosser J; Oger E; Adamski H; Galibert MD; Lesimple T
    J Eur Acad Dermatol Venereol; 2015 Aug; 29(8):1530-8. PubMed ID: 25623140
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Systemic treatment of melanoma brain metastases].
    Le Rhun É; Mateus C; Mortier L; Dhermain F; Guillot B; Grob JJ; Lebbe C; Thomas M; Jouary T; Leccia MT; Robert C
    Cancer Radiother; 2015 Feb; 19(1):48-54. PubMed ID: 25656856
    [TBL] [Abstract][Full Text] [Related]  

  • 46. MEK inhibition, alone or in combination with BRAF inhibition, affects multiple functions of isolated normal human lymphocytes and dendritic cells.
    Vella LJ; Pasam A; Dimopoulos N; Andrews M; Knights A; Puaux AL; Louahed J; Chen W; Woods K; Cebon JS
    Cancer Immunol Res; 2014 Apr; 2(4):351-60. PubMed ID: 24764582
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Update on Immunotherapeutics in the Management of Metastatic Melanoma.
    Bulir D; Liang S; O’Malley M; McWhirter E
    Skin Therapy Lett; 2019 Jan; 24(1):8-11. PubMed ID: 30817881
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Current status and future directions of molecularly targeted therapies and immunotherapies for melanoma.
    Miller DM; Flaherty KT; Tsao H
    Semin Cutan Med Surg; 2014 Jun; 33(2):60-7. PubMed ID: 25085663
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Targeting BRAF in melanoma: biological and clinical challenges.
    Mandalà M; Voit C
    Crit Rev Oncol Hematol; 2013 Sep; 87(3):239-55. PubMed ID: 23415641
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Discovery of a novel ERK inhibitor with activity in models of acquired resistance to BRAF and MEK inhibitors.
    Morris EJ; Jha S; Restaino CR; Dayananth P; Zhu H; Cooper A; Carr D; Deng Y; Jin W; Black S; Long B; Liu J; Dinunzio E; Windsor W; Zhang R; Zhao S; Angagaw MH; Pinheiro EM; Desai J; Xiao L; Shipps G; Hruza A; Wang J; Kelly J; Paliwal S; Gao X; Babu BS; Zhu L; Daublain P; Zhang L; Lutterbach BA; Pelletier MR; Philippar U; Siliphaivanh P; Witter D; Kirschmeier P; Bishop WR; Hicklin D; Gilliland DG; Jayaraman L; Zawel L; Fawell S; Samatar AA
    Cancer Discov; 2013 Jul; 3(7):742-50. PubMed ID: 23614898
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Resistance to MEK inhibitors: should we co-target upstream?
    Poulikakos PI; Solit DB
    Sci Signal; 2011 Mar; 4(166):pe16. PubMed ID: 21447797
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Metastatic Melanoma: Recent Therapeutic Progress and Future Perspectives.
    Malissen N; Grob JJ
    Drugs; 2018 Aug; 78(12):1197-1209. PubMed ID: 30097888
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Acquired resistance to BRAF inhibition can confer cross-resistance to combined BRAF/MEK inhibition.
    Gowrishankar K; Snoyman S; Pupo GM; Becker TM; Kefford RF; Rizos H
    J Invest Dermatol; 2012 Jul; 132(7):1850-9. PubMed ID: 22437314
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Combination of pan-RAF and MEK inhibitors in NRAS mutant melanoma.
    Atefi M; Titz B; Avramis E; Ng C; Wong DJ; Lassen A; Cerniglia M; Escuin-Ordinas H; Foulad D; Comin-Anduix B; Graeber TG; Ribas A
    Mol Cancer; 2015 Feb; 14(1):27. PubMed ID: 25645078
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Synergistic effects of eIF4A and MEK inhibitors on proliferation of NRAS-mutant melanoma cell lines.
    Malka-Mahieu H; Girault I; Rubington M; Leriche M; Welsch C; Kamsu-Kom N; Zhao Q; Desaubry L; Vagner S; Robert C
    Cell Cycle; 2016 Sep; 15(18):2405-9. PubMed ID: 27533468
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Combination therapy of melanoma using kinase inhibitors.
    Heppt MV; Tietze JK; Graf SA; Berking C
    Curr Opin Oncol; 2015 Mar; 27(2):134-40. PubMed ID: 25602684
    [TBL] [Abstract][Full Text] [Related]  

  • 57. BRAF and MEK inhibition variably affect GD2-specific chimeric antigen receptor (CAR) T-cell function in vitro.
    Gargett T; Fraser CK; Dotti G; Yvon ES; Brown MP
    J Immunother; 2015 Jan; 38(1):12-23. PubMed ID: 25415284
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Vertical inhibition of the MAPK pathway enhances therapeutic responses in NRAS-mutant melanoma.
    Rebecca VW; Alicea GM; Paraiso KH; Lawrence H; Gibney GT; Smalley KS
    Pigment Cell Melanoma Res; 2014 Nov; 27(6):1154-8. PubMed ID: 25130256
    [TBL] [Abstract][Full Text] [Related]  

  • 59. NRAS mutant melanoma: biological behavior and future strategies for therapeutic management.
    Fedorenko IV; Gibney GT; Smalley KS
    Oncogene; 2013 Jun; 32(25):3009-18. PubMed ID: 23069660
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Concomitant targeting of programmed death-1 (PD-1) and CD137 improves the efficacy of radiotherapy in a mouse model of human BRAFV600-mutant melanoma.
    Kroon P; Gadiot J; Peeters M; Gasparini A; Deken MA; Yagita H; Verheij M; Borst J; Blank CU; Verbrugge I
    Cancer Immunol Immunother; 2016 Jun; 65(6):753-63. PubMed ID: 27160390
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.